Immuno-oncology combos – what will be hot in 2018?

Source EP Vantage
Company IncyteArray BioPharmaBristol-Myers SquibbMerck & CoMerck KGaARocheNektar TherapeuticsAstraZenecaPfizerInnate PharmaFive Prime TherapeuticsJounce TherapeuticsCURED 
Tags Event - Open, Trial Results, Therapeutic Focus, Free Content, Company Strategy, Oncology, Analysis
Date November 28, 2017

The past couple of years have seen a surge in the number of immuno-oncology combination trials, though the tidal wave of research has yet to yield conclusive clinical benefits. This could change in 2018, with numerous studies of novel targets including Lag3, CD122 and Icos  due to read out (see tables below).

The most eagerly awaited is IDO inhibition, with Incyte  due to unveil results from the hugely important Echo-301 study. Hopes are high that combination strategies can be found to add to the strong benefits seen with PD-(L)1 blockade, but caution is warranted. Progress will be slow, and next year could see ambiguous or incremental steps rather than huge leaps onward.

Incyte  hopes for the latter, of course, and a lot is riding on succesful readout of the first rigorous phase III data in this space. Echo-301 tests a combination of epacadostat with  Merck & Co ’s Keytruda in first-line melanoma, a tumour type that has already been transformed by the arrival of the anti-PD-1 antibodies.

The sellside has built huge expectations around the asset – consensus has epacadostat becoming a blockbuster by 2021, according to EvaluatePharma – and  Incyte  has a market value to match: $21bn.

These figures reflect success in more than melanoma; studies are ongoing in lung, bladder and kidney cancers among others, under various collaborations with owners of anti-PD(L)1 antibodies. A hit in melanoma, which is highly immunogenic, is crucial if wider benefits are to be inferred. Failure in this setting would not only cause Incyte  to crash, but could also dent optimism in other I-O combinations.

Keeping an eye on I-O: checkpoint targets trials to watch out for in 2018 
Target  Project  Company   Study, indication, combo  Trial ID 
Going up… 
IDO  Epacadostat  Incyte   Echo-301: melanoma; + Keytruda  NCT02752074 
Lag3  Relatlimab (BMS-986016)   Bristol-Myers Squibb  Checkmate-142: Colorectal cancer, + Opdivo  NCT02060188 
CD122 (IL-2Rβ)  NKTR-214  Nektar Therapeutics   Pivot02: + Keytruda. Propel: + Opdivo, + Tecentriq  NCT02983045; NCT03138889  
…and going down 
Ox40  PF-04518600  Pfizer /Merck KGaA  Javelin Medley: + Bavencio  NCT02554812 
CSF-1R  Cabiralizumab   Bristol-Myers Squibb/Five Prime  + Opdivo  NCT02526017 
CSF-1R  ARRY-382  Array   + Keytruda   NCT02880371 
CSF-1R  Emactuzumab  Roche   + Tecentriq  NCT02323191 
CSF-1R  PD-0360324  Pfizer /Merck KGaA  Javelin Medley: + Bavencio    NCT02554812 

Another key I-O target is Lag3, where Bristol’s relatlimab already showed efficacy at the recent SITC meeting in Lag3-positive patients who had progressed on anti-PD-(L)1 therapy. Several early trials might yield additional data, but most keenly awaited will be Bristol’s Checkmate-142 colorectal cancer combo with Opdivo.

Meanwhile, Nektar made waves at SITC when it showed that its CD122 agonist NKTR-214 combined with Opdivo prompted responses in PD-L1-negative subjects, raising hopes that it could turn “cold” tumours “hot”. Still, there were just 36 patients here, and further updates from two NKTR-214 studies will be keenly awaited in 2018 (SITC – Nektar’s plan to make cold tumours blossom, November 14, 2017).

An especially important trial to watch, according to Evercore ISI’s Jon Miller, is Pfizer /Merck KGaA’s Javelin Medley, which looks at combining Ox40, 4-1BB and CSF-1R targeting with Bavencio, as well as a triple combo comprising the Ox40 and 4-1BB agents plus Bavencio.

Still, Mr Miller admits that Ox40 has fallen out of favour as a next-generation candidate – Roche  went so far as abandoning its asset RG7888.

A similar assessment could be made of CSF-1R, after Five Prime’s cabiralizumab abstract at SITC disappointed investors, raising perhaps unfounded questions over toxicity, and doubts over incremental efficacy over Opdivo (“Surprise” SITC late-breaker breaks Five Prime, November 8, 2017).

What and where?

No doubt more information will emerge next year about pharmacology. Some I-O combo approaches, like PD-(L)1 and CTLA4, largely aim to release two brakes on the immune system. Others, like those involving 4-1BB, concern a general immune system activation, while others still are more subtle. Many, of course, have yet to be fully understood.

Innate Pharma’s failure with lirilumab, the sole Kir-targeting asset, seems to have been explained by novel understanding that hitting this NK checkpoint is complicated by the fact that a negative feedback loop of sorts subsequently prevents those NK cells from maturing (The market writes off lirilumab, November 23, 2017).

It is highly likely that other novel mechanisms will unravel when tested in larger studies, or that encouraging monotherapy data fails to translate into a viable combination strategy.

Other checkpoints are involved in cell infiltration, rather than merely activation/inactivation. For instance, Icos  ligand blockade – important for the recently floated Jounce – might be involved in T regulatory cell depletion, while Lag3 plays a complex role in activation of antigen-presenting cells, and CSF-1R is thought to inhibit activation and signalling in another cell type – the tumour-associated macrophage.

Mr Miller says he is also looking forward to data on generally immunostimulating targets like Sting, IL-2, IL-12 and TLRs. The tables in this analysis represent only a tiny slice of the clinical effort, and data will emerge from many other studies.

Still, concern has already been growing that expectations are too high given how slow progress has been in this field, and the disappointments with Ox40, CSF-1R and Kir bear out some of these worries. Investors have thus been served several reminders that the questions of what to combine and where are not easily answered.

Sean Bohen, chief medical officer at Astrazeneca , cautioned recently that it would take time to answer these questions empirically through clinical trials.

“There is sometimes a bit of exuberance that we’ve cured  cancer – I’ve seen it through multiple mechanisms in my career, and the latest is certainly I-O,” Mr Bohen said at a press conference in October. “What is remarkable – and I don’t think there’s any irrationality in the exuberance around this – is that some subsets of patients seem to have a really durable benefit.”  

Identifying who these patients are, and whether the group can be expanded by using combinations, represent formidable challenges.

Keeping an eye on I-O: other combo trials to watch out for in 2018 
Project and target  Company   Study, indication, combo  Trial ID 
MBG453  Novartis   + PDR001 (PD-1)  NCT02608268 
TSR-022  Tesaro   Amber: + TSR-042 (PD-1)  NCT02817633 
RG7876  Roche   + emactuzumab  NCT02760797 
JTX-2011  Celgene /Jounce  Iconic: + Opdivo  NCT02904226 
GWN323  Novartis   + PDR001 (PD-1)  NCT02740270 
Cergutuzumab  Roche   + Tecentriq  NCT02350673 
CMP-001   Checkmate Pharmaceuticals   Melanoma, + Keytruda  NCT02680184 
IMO-2125  Idera Pharmaceuticals   Melanoma, + Yervoy  NCT02644967 
4-1BB (CD137) 
Utomilumab  Pfizer /Merck KGaA  Javelin Medley: + Bavencio    NCT02554812 
Urelumab  Bristol-Myers Squibb  Includes B-cell NHL, GBM; + Opdivo  NCT02253992; NCT02658981 

EP Vantage’s immuno-oncology combination report can be downloaded here.

An EP Vantage staff report. To contact the writers of this story email or follow  @EPVantage on Twitter

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to:

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM
©2018 EP Vantage Ltd